Phase I drug combination trial design: Walking the tightrope
2009-09-20
Article
volume 27, issue 27 pp 4441-4443.
| Related Files |
|---|
|
Redirect to publisher's version
(publisher's version.url.txt, 42 bytes) |
Keywords
- human
- priority journal
- clinical trial
- cisplatin
- treatment outcome
- cancer patient
- incidence
- squamous cell carcinoma
- editorial
- drug safety
- cancer combination chemotherapy
- advanced cancer
- febrile neutropenia
- fluorouracil
- gastrointestinal toxicity
- cetuximab
- docetaxel
- maximum tolerated dose
- phase 1 clinical trial
- cancer palliative therapy
- head and neck carcinoma
- local therapy
